• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Mirum Pharmaceuticals Acquires San Diego-based Satiogen

    Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals

    Insmed Appoints Drayton Wise as Chief Commercial Officer

    Clinigen Expands U.S. Site Capacity

    Corealis CDMO Completes Deal with ArchiMed
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Risk Assessment for a Nitrosamine Contamination of Peptide APIs Manufactured by SPPS

    Clinigen Expands U.S. Site Capacity

    Corealis CDMO Completes Deal with ArchiMed

    Piramal Pharma Solutions Upgrades Oral Solid Dose Capabilities

    Lonza, IBF Partner on Drug Development, Manufacture for Portfolio Cos
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    How Can Automation Optimize Immunohistochemistry?

    Corealis CDMO Completes Deal with ArchiMed

    Lonza, IBF Partner on Drug Development, Manufacture for Portfolio Cos

    Aptamer Group and PinotBio Extend Collaboration Agreement

    Selecting a CMO Partner for Sterile Injectable Manufacturing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    IDT Biologika

    Quotient Sciences

    Kyongbo Pharmaceutical

    Biosynth Carbosynth
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    IDT Biologika

    Quotient Sciences

    Kyongbo Pharmaceutical

    Biosynth Carbosynth
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Contract Pharma’s 20th Anniversary Series: CDMO Insight

    JoyL Silva of Pfizer CentreOne discusses global market and regulatory changes driving drug development strategies and the evolution of CDMO services and ops.

    Contract Pharma’s 20th Anniversary Series: CDMO Insight
    Related CONTENT
    • Legacy Pharma Solutions
    • Pfizer CentreOne
    • PCI Pharma Services
    • Oxford Lasers Imaging Division
    • Catalent Pharma Solutions
    Kristin Brooks, Contract Pharma11.01.19
    In looking at the past 20 years, the following offers additional insight into the CDMO industry and the key trends influencing outsourcing. JoyL Silva, General Manager, Pfizer CentreOne discusses global market changes, some of the major regulatory changes driving drug development strategies, and the evolution of CDMO services and operations. –KB
     
    Contract Pharma: How have pharma/biopharma industry changes impacted CDMOs over the years?
     
    JoyL Silva: With the growing number of options available, selecting the right CDMO partner is an even more critical decision for drug developers. The top five end-to-end CDMOs still only comprise 15 percent of the market.1 Beyond these, there are about 300 to 400 others vying for contract work.2 This makes the process of finding the right contract manufacturer and best fit for particular projects relatively complex.
     
    The demand for contract partners able to fulfil end-to-end drug strategies makes up only a portion of pharma’s demand for contract development and manufacturing services. Even though end-to-end CDMOs are often consulted for their breadth of services (i.e., early development, clinical to commercial, finished drug product), CDMO services and capacity are in demand to support drug strategies in other, more focused ways; as a reliable commercial capacity second source supplier or to assist a customer with a specific development request.
     
    Not all customers need or require end-to-end solutions and what shapes demand for contract services in general is as diverse as the global pharma industry is today.
     
    That means that there is still plenty of demand for a wide range of CMO and CDMO manufacturing and development services, especially those offering particular experience and expertise.
     
    For the foreseeable future, pharma’s innovators will continue to demand a wide range of CDMO services, while seeking expert and collaborative partners with the experience to make even the most ambitious drug strategies possible.
     
    CP: What global market changes have had the greatest impact on the industry and CDMO services? 
     
    JS: Several important trends are shaping the CDMO landscape and influencing how pharma is engaging the industry.
     
    For one, aseptic drug manufacturing and sterile fill-finish operations are proving to be extremely challenging for the industry. It’s a global issue and proving to be a tremendous ‘disruptor’ with sterility and quality excursions threatening critical supplies of certain therapeutics including vaccines, antibiotics and sterile liquids like saline.
     
    The ascent of biopharmaceutical science prompted dramatic change. The increasing global consumption of biopharmaceuticals has led to a growing demand for outsourcing partners capable of making these hard-to-make large-molecule drugs in sufficient volumes to reach underserved patient groups around the world.
     
    Innovation in drug form and drug delivery are creating complexities for the industry as well. Influenced by a variety of pharmacokinetic and pharmacodynamic characteristics of today’s formulations, contract manufacturers are being tasked to develop and manufacture even more sophisticated API/delivery/device combinations to serve bioavailability challenges, unmet patient needs while delivering better dose compliance therapeutic effect among other goals.
     
    Similarly, biopharma’s drug innovators are also seeking highly competent partners to develop and commercialize their very small batches of novel, hard-to-make biopharmaceutical APIs and drug products. Many of today’s therapeutics require specialty partners with the skills and experience to develop and manufacture innovations successfully.
     
    Now CDMOs are needed as technological leaders and strategic collaborators to form strong, sustainable partnerships. Our job is to help our customers understand the optimal routes for their drug strategies and uncover the best tactics to get a reliable supply of their products to patients.
     
    CP: What are some of the major regulatory changes that have impacted the industry over the years?
     
    JS: One major regulatory driver impacting drug strategies over the past 20 years has been the FDA’s unwavering focus on patient safety and the therapeutic effectiveness and value of medications. Recent guidance on continuous manufacturing and quality by design manufacturing concepts for example, is prompting innovation and new capital investment to assure quality and lower manufacturing costs.
     
    In 1990, Congress amended the Federal Food, Drug and Cosmetic Act to introduce the concept of combination products and to clarify specific control strategies for these types of products. In general, a combination product is a product made up of two or more FDA-regulated components that are intended for use together.
     
    Drug, biologic and device combination products can make treatments safer, more effective and/or more convenient for patients. Obtaining approval for a combination product, however, involves complexities beyond a typical drug or device development program. Not only are the regulations for combination products complex, but they are also not yet globally harmonized. Close attention to the evolution of combination product regulations around the world is needed if your business is supporting this type of development program.
     
    Since about 2008, the US pipeline of drugs submitted for approval has steadily filled with novel New Drug Applications (NDAs) followed by a flood of FDA approvals. In 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA) was enacted by congress which accelerated the trend. The law created the Breakthrough Therapy Designation (BTD) to identify promising new drugs earlier in clinical development with the potential to demonstrate substantial improvement over existing therapies treating serious chronic and life-threatening disease states. Over the past 10 years, the use of expedited approval pathways has significantly increased.
     
    In a recent article written by FDA’s Janet Woodcock, M.D., (Director, Center for Drug Evaluation and Research) and Peter Marks, M.D., Ph.D., (Director, Center for Biologics Evaluation and Research)3 it was noted that a misconception that FDA’s increasing use of Expedited Approval programs over the last decade, may be driven by a loosening of their approval standards. They mention that the reality of the situation is that the FDA’s standards have not changed, but instead, the increased use of expedited approval pathways is directly related to the increasing numbers and scope of these programs provided by Congress, as well as the kinds of medicines that are being developed, and the types of diseases that are being studied. The article shares a few facts to illustrate the rapid evolution underway in drug discovery and development:
     
    ·       Only 157 orphan drugs (those that treat rare diseases) were approved in the ten-year period, 1999 through 2008, whereas 436 have been approved in the 10-year period, 2009 through 2018. Orphan drugs are often candidates for expedited programs.
    ·       The portfolio of cancer drugs, many for people lacking other options, has rapidly grown to currently comprise more than a third of novel drug approvals.
    ·       In the last two years, FDA has approved the first four cell and gene therapy products, and now has more than 800 active investigational new drugs of this type under review — signalling the leading edge of a wave of these new therapies.
     
    As the regulatory environment continues to evolve, it is critical to rely on a partner that can cope with the changes and innovate successfully enough to keep up. Our focus on intelligent collaboration with our customers is helping to ensure successful outcomes of their drug development strategies—something that many rely on, especially patients who have the ultimate need for these important medicines.
     
    References
    1.     https://www.outsourcing-pharma.com/Article/2018/10/22/Top-5-CDMOs-hold-15-of-the-market-as-industry-consolidation-is-expected-to-continue#
    2.     http://www.kurmannpartners.com/fileadmin/user_upload/_temp_/KP_Pharma_M_A_Report_2018_-_medium.pdf
    3.     https://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-and-experts/delivering-promising-new-medicines-without-sacrificing-safety-and-efficacy

    Related Searches
    • vaccines
    • clinical development
    • fda
    • Manufacturing
    Suggested For You
    Legacy Pharma Solutions Legacy Pharma Solutions
    Pfizer CentreOne Pfizer CentreOne
    PCI Pharma Services PCI Pharma Services
    Oxford Lasers Imaging Division Oxford Lasers Imaging Division
    Catalent Pharma Solutions Catalent Pharma Solutions
    Mogene Mogene
    Regis Custom Pharma Regis Custom Pharma
    Mikart Mikart's Gus Labella
    Exelead Exelead's Alex Aust
    Alcami Alcami's Brittany Jackway
    Federal Equipment Federal Equipment's Adam Covitt
    FDA Leaders Address Drug Shortages FDA Leaders Address Drug Shortages
    Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future
    Altasciences Altasciences
    Adare Pharma Solutions Adare Pharma Solutions

    Related Content

    • Legacy Pharma Solutions

      Legacy Pharma Solutions

      ...
      Nathan Bender, Director, Sales & Marketing 12.07.21

    • Injectables
      Pfizer CentreOne

      Pfizer CentreOne

      ...
      Robert Smith, Digital Marketing Manager 11.30.21

    • Drug Development
      PCI Pharma Services

      PCI Pharma Services

      ...
      Jessica Kloster, Marketing Manager 10.20.21


    • Oxford Lasers Imaging Division

      ...
      Carla Taylor, Marketing 10.12.21

    • Drug Delivery
      Catalent Pharma Solutions

      Catalent Pharma Solutions

      ...
      Christopher, Director, Global Communications and Marketing 11.25.20

      Trending
      • How Can Automation Optimize Immunohistochemistry? | Contract Pharma
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Corealis CDMO Completes Deal With ArchiMed | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • Lonza Invests In Additional Inhalation Capabilities In Tampa | Contract Pharma
      Breaking News
      • CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen
      • Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
      • Insmed Appoints Drayton Wise as Chief Commercial Officer
      • Clinigen Expands U.S. Site Capacity
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      PPG Hosts The Future of Coatings' Technology Innovation Day in Amsterdam
      Azelis Expands Presence in India with Acquisition of Chemo India and Unipharm Laboratories
      Teknos Publishes Sustainability Report
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Solid Growth Expected for India's Medical Device Sector
      Hologic Gains CE Mark for 2 Molecular Assays for Transplant Patients
      Vector Remote Care Rolls Out New Cardiac Care Software Platform
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Mirum Pharmaceuticals Acquires San Diego-based Satiogen
      Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
      Insmed Appoints Drayton Wise as Chief Commercial Officer
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      La Roche-Posay Launches Matte Moisturizer for Oily Skin
      3 Amorepacific Employees Stole $2.3 Million
      L'Oreal CEO Nicolas Hieronimus On Sustainability Initiatives
      Happi

      Latest Breaking News From Happi

      Thayers Natural Remedies Celebrates 175 Years with Social Campaign
      Former Model Shirley Powell’s Indie Beauty Brand LaJeanell Comprises Gender Inclusive Skincare and Makeup
      L’Oréal's New UVMune 400 Sun Filtering Technology Protects Skin From Ultra-Long UVA Rays
      Ink World

      Latest Breaking News From Ink World

      NAPIM’s Virtual Digital & Emerging Technologies Conference is Back, June 14–15, 2022
      CEMATEX Introduces Online Business Platform to Connect Global Textile Community
      PICO Chemical Celebrates 46 Years
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      AWA to host 22nd Global Release Liner Industry Conference & Exhibition
      Domino assists Grace Label with supply chain disruptions
      Rotocon wins AI Business Excellence Award
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Emovi, Geneva Foundation Providing Knee Treatment Tech to U.S. Army
      Study Confirms Knee Shapes are Highly Individualized
      Stryker Launches EasyFuse Dynamic Compression for Foot & Ankle
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Avery Dennison Launches AD Twist U7XM Inlays
      ARPA-E Funding Drives Innovation, Industry Partnerships at NREL
      InnovationLab Acquires Flexible Printed Battery Technology from Evonik

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login